Market Place
Sourcing Support
Intellia, Alnylam post data on contrasting cardiomyopathy ideas
18 Nov 2024 //
FIERCE BIOTECH
Intellia Announces 1st Clinical Evidence Of Nexiguran Ziclumeran
16 Nov 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Q3 2024 Results & Company Progress
07 Nov 2024 //
GLOBENEWSWIRE
Intellia Reports Inducement Grants under Nasdaq LR 5635(c)(4)
05 Nov 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Announces Two Investor Events in November
31 Oct 2024 //
GLOBENEWSWIRE
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks
24 Oct 2024 //
FIERCE BIOTECH
Intellia Presents Positive Phase 2 Results For NTLA-2002 HAE
24 Oct 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Announces New Date for Investor Webcast
10 Oct 2024 //
GLOBENEWSWIRE
Intellia starts late-stage test of CRISPR for rare swelling disease
08 Oct 2024 //
BIOPHARMADIVE
Intellia Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
03 Oct 2024 //
GLOBENEWSWIRE
Intellia Presents Phase 1 Data on nexiguran for ATTR Amyloidosis
01 Oct 2024 //
GLOBENEWSWIRE
Intellia To Present NTLA-2002 Phase 2 Data At ACAAI Annual Meeting
12 Sep 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Reports Inducement Grants under Nasdaq Rule 5635(c)(4)
03 Sep 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Announces Q2 2024 Results And Company Progress
08 Aug 2024 //
GLOBENEWSWIRE
Intellia Therapeutics To Hold Q2 2024 Earnings Call
01 Aug 2024 //
GLOBENEWSWIRE
Bioventus To Report Q2 2024 Results On August 6
30 Jul 2024 //
GLOBENEWSWIRE
Intellia Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
24 Jul 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Announces CFO Transition
26 Jun 2024 //
GLOBENEWSWIRE
Intellia Shows Re-Dosing Possible for NTLA-2001
25 Jun 2024 //
FIERCE BIOTECH
Intellia Announces Positive Data for Redosing CRISPR-Based Therapy
25 Jun 2024 //
GLOBENEWSWIRE
Intellia To Present Clinical Data On Redosed In Vivo CRISPR Therapy At PNS 2024
17 Jun 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Names Brian Goff to its Board of Directors
14 Jun 2024 //
GLOBENEWSWIRE
Intellia Announces Positive Long-Term Data from Ongoing Ph1 Study of NTLA-2002
03 Jun 2024 //
PRESS RELEASE
Intellia`s NTLA-2002 Gene Editing Shows Positive HAE Long-Term Data
02 Jun 2024 //
GLOBENEWSWIRE
Intellia Therapeutics Q1 2024 Results And Company Highlights
09 May 2024 //
GLOBENEWSWIRE
Intellia Q1 2024 Earnings Call, Company Updates
02 May 2024 //
GLOBENEWSWIRE
Intellia to Present NTLA-2002 Updates in HAE at EAACI 2024
29 Apr 2024 //
GLOBENEWSWIRE
Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise
22 Mar 2024 //
ENDPTS
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 of NTLA-2001
18 Mar 2024 //
GLOBENEWSWIRE
Is Intellia Therapeutics Stock a Buy Now
08 Mar 2024 //
FOOL
Intellia Therapeutics Announces Q4 & Full-Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration
15 Feb 2024 //
PRESS RELEASE
Intellia Therapeutics to Discuss Fourth Quarter and Full-Year 2023 Earnings
14 Feb 2024 //
GLOBENEWSWIRE
Intellia Announces Publication of Positive Interim Phase 1 Data for NTLA-2002
31 Jan 2024 //
GLOBENEWSWIRE
Intellia Therapeutics cuts 15% of workforce, extends cash runway into mid-2026
05 Jan 2024 //
ENDPTS
Intellia Therapeutics Highlights its Three-Year Strategic Priorities
04 Jan 2024 //
GLOBENEWSWIRE
Intellia, Aera the latest gene editing biotechs to lay off staff
04 Jan 2024 //
FIERCE BIOTECH
Intellia Therapeutics Inc (NTLA): An Important Analyst Insights
14 Dec 2023 //
STOCK REGISTER
Intellia Receives European Union Orphan Drug Designation for NTLA-2002
14 Nov 2023 //
GLOBENEWSWIRE
Intellia Therapeutics Announces Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Trio of biotechs toss programs to discard pile
09 Nov 2023 //
FIERCE BIOTECH
Intellia suggests ATTR amyloidosis treatment has over a year of durability
02 Nov 2023 //
ENDPTS
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001
02 Nov 2023 //
GLOBENEWSWIRE
Intellia Therapeutics to Present Data from Ongoing Phase 1 Study of NTLA-2001
26 Oct 2023 //
GLOBENEWSWIRE
Intellia preps first ph. 3 trial of in vivo CRISPR therapy in US
18 Oct 2023 //
FIERCE BIOTECH
Intellia Therapeutics Receives PRIME Designation From EMA for NTLA-2002
13 Oct 2023 //
GLOBENEWSWIRE
Regeneron and Intellia Announce Collaboration to Develop CRISPR-Based Therapies
03 Oct 2023 //
GLOBENEWSWIRE
Intellia, Verve run trials abroad amid FDA’s ‘cautious’ approach to gene editing
17 Aug 2023 //
ENDPTS
Intellia Therapeutics Announces Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Intellia fills gene editing trial outside US after FDA request
03 Aug 2023 //
FIERCE BIOTECH
Intellia Therapeutics to Hold Conference to Discuss Second Quarter 2023 Earnings
27 Jul 2023 //
GLOBENEWSWIRE
Intellia Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002
11 Jun 2023 //
GLOBENEWSWIRE
Intellia Announces Retirement of Jean-Fran§ois Formela From Board of Directors
05 Jun 2023 //
GLOBENEWSWIRE
Intellia to Present Updated Interim Data from Phase 1/2 Study of NTLA-2002
31 May 2023 //
GLOBENEWSWIRE
Intellia Therapeutics Announces 1Q 2023 FYR & Highlights Recent Company Progress
04 May 2023 //
GLOBENEWSWIRE
Intellia Releases 2023 Corporate Responsibility Report Highlighting
01 May 2023 //
GLOBENEWSWIRE
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023
27 Apr 2023 //
GLOBENEWSWIRE
Intellia Therapeutics Names Bill Chase to its Board of Directors
17 Apr 2023 //
GLOBENEWSWIRE
Intellia Therapeutics Announces FDA RMAT Designation Granted to NTLA-2002
21 Mar 2023 //
GLOBENEWSWIRE
Intellia shares jump as gene therapy trial gets U.S. regulator nod
03 Mar 2023 //
ENDPTS
